Long read Hydroxychloroquine: A Morality Tale by Norman Doidge
“ The Henry Ford study also studied HCQ in combination with azithromycin to improve outcomes, and it did. It specified all doses, seemed to get them right, and gave them at the proper time, early, right after admission, which as we’ve seen, is crucial to precede the cytokine storm. The study followed the patient’s electrocardiograms (ECGs), and heart status throughout, checking for any of the alleged cardiac problems, to make sure the HCQ didn’t cause harm. It found that with early prescription of HCQ (82% within 24 hours of hospitalization, 91% within 48 hours), the patients had far fewer cardiac problems than are usually seen in later stages of COVID. Since this study, multiple studies have come out showing that HCQ, when properly monitored, is notassociated with increased cardiac fatalities. The authors made the very sensible point, that it is probably the case that we will have to work with several drugs to treat this disease, and the combinations will likely be different for different patients. Imagine.”
That is just one except. There is a lot more in the article. A shorter version is needed.
A shorter article on a much touted drug https://science.thewire.in/the-sciences/remdesivir-clinical-trial-jama-gilead-bad-science/
“ The Henry Ford study also studied HCQ in combination with azithromycin to improve outcomes, and it did. It specified all doses, seemed to get them right, and gave them at the proper time, early, right after admission, which as we’ve seen, is crucial to precede the cytokine storm. The study followed the patient’s electrocardiograms (ECGs), and heart status throughout, checking for any of the alleged cardiac problems, to make sure the HCQ didn’t cause harm. It found that with early prescription of HCQ (82% within 24 hours of hospitalization, 91% within 48 hours), the patients had far fewer cardiac problems than are usually seen in later stages of COVID. Since this study, multiple studies have come out showing that HCQ, when properly monitored, is notassociated with increased cardiac fatalities. The authors made the very sensible point, that it is probably the case that we will have to work with several drugs to treat this disease, and the combinations will likely be different for different patients. Imagine.”
That is just one except. There is a lot more in the article. A shorter version is needed.
A shorter article on a much touted drug https://science.thewire.in/the-sciences/remdesivir-clinical-trial-jama-gilead-bad-science/
No comments:
Post a Comment